Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
6 U.S. States for Climbing - 2Which '80s Film Actually Holds Up Today?
- 3Eurovision Song Contest changes voting rules after controversial allegations against Israel
- 4Modern surgery began with saws and iron hands – how amputation transformed the body in the Renaissance
- 5Common ADHD medication prescribed in childhood may protect against risk of psychosis
- What is the Significant Tech Expertise to Master Today?
- Boeing's troubled capsule won't carry astronauts on next space station flight
- Individual Preparation Administrations to Raise Your Wellness Process
- Why Tourists May Want To Reconsider Traveling To This Popular Spot In Italy In 2026
- German politician urges more face-to-face interaction in digital age
- The Most Rousing Ladies Business visionaries of Today
- Figurine of a woman and a goose offers peek at prehistoric beliefs
- 'Spending more on gas than groceries:' Rising fuel prices drive more San Antonio families to the Food Bank amid Iran war
- What's your #1 tone
